Ozempic Maker's Parent Company To Invest $7B Annually By 2030: 'We Have More Money Than Ever To Invest'
Novo Holdings’ CEO, Kasim Kutay, highlighted that the increasing income from its investments and the success of Novo Nordisk’s drugs like Ozempic and Wegovy drive this decision. The fund surge will be equally distributed between capital and life sciences investments.
Transcript
00:00 [MUSIC PLAYING]
00:03 [MUSIC PLAYING]
00:06 [MUSIC PLAYING]
00:10 [MUSIC PLAYING]
00:13 [MUSIC PLAYING]
00:17 [MUSIC PLAYING]
00:21 [MUSIC PLAYING]
00:26 [MUSIC PLAYING]
00:30 [MUSIC PLAYING]
00:35 [MUSIC PLAYING]
00:40 (upbeat music)
00:42 (upbeat music)
00:45 (upbeat music)
00:47 (upbeat music)
00:53 (upbeat music)
00:57 (upbeat music)
01:02 (upbeat music)
01:04 (upbeat music)
01:07 you